Thrombophilic status may predict prognosis in patients with metastatic BRAFV600- mutated melanoma who are receiving BRAF inhibitors Anna Falanga, MD,

Slides:

Advertisements

Similar presentations

Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC) Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,

Advertisements

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

CD47 expression for in situ and invasive cutaneous epithelial lesions

A girl with a solitary red bulla

Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh Adam Ingraffea, BA, Kevin Donohue, MD, Caroline Wilkel, MD,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

The adverse prognostic effect of tumor budding on the evolution of cutaneous head and neck squamous cell carcinoma Miriam Gonzalez-Guerrero, MD, Pablo.

Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: Report of three cases Xiaoqing.

Sweet's panniculitis associated with metastatic breast cancer

Baldness reversed by chemotherapy

Squamous cell carcinoma over tattoos

Expression of PD-L1 in mastocytosis

Extensive ulcerated pigmented nodules

Jacqueline J. Russo, MD, Keira L. Barr, MD, Larissa Z

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin Jennifer Lin, MD, Jason P.

High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma

Primary thyroid marginal zone B-cell lymphoma in a patient with psoriatic arthritis treated with etanercept Hyunju Jin, MD, Hyun-Ho Cho, MD, Won-Jeong.

Ben Tallon, MBChB, Elizabeth Blanchard, MD, Lynne J. Goldberg, MD

Cholangiocarcinoma with skin metastases

Squamous cell carcinoma tumor thrombus encountered during Mohs micrographic surgery Gary Mendese, MD, Jeremy Bordeaux, MD, MPH, Sean Pattee, MD, Mary.

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation Julie Charles, MD, PhD, Jean-Claude.

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival Junna Oba, MD, PhD, Takeshi Nakahara,

Mid-dermal elastolysis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient Carlo Cota, MD, Alessandra Latini,

JAK inhibitors in dermatology: The promise of a new drug class

High specificity and sensitivity of NRAS Q61R immunohistochemistry (IHC) in melanomas Pierre-Alexandre Just, MD, PhD, Christelle Pouliquen, MD, Anne.

A definitive case of metastatic folliculotropic melanoma

Classic pseudoxanthoma elasticum in a patient with sickle cell disease

Whitney A. High, MD, MEng, Reed A

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site Hye Rim Moon, MD, Hyun Ji Kang, MD,

Myiasis in a giant squamous cell carcinoma

Reply to: “A note on normality”

Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD

Volume 3, Issue 1, Pages (January 2017)

The applicability and prognostic value of the TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome.

Solitary mastocytoma in an adult with an unusual clinical presentation

“Strawberry gums” in sarcoidosis

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Fever, eosinophilia, and a rash

Infectious rash after riding elephants

A case of adult T-cell leukemia/lymphoma in the Midwest

Sajjad P. Syed, MD, David G. Brooks, MD, Helen M

Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma Antonio Martorell, MD, Fernando Millan-Parrilla, MD, Enrique Gimeno-Carpio,

Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome Alexander Kreuter, MD, Peter Altmeyer, MD

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases Alan S. Boyd, MD, Bashar Shakhtour,

Reflectance confocal microscopy of pigmented basal cell carcinoma

Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients Véronique.

Solomon Shockman, MD, Lauren Krug, MD, Nektarios Lountzis, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Plasmacytoid dendritic cell involvement in the host response against keratoacanthoma Ossama Abbas, MD, Lama Hussein, MD, Mazen Kurban, MD, Abdul-Ghani.

Reduced membranous β-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus Po-Kuei.

BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors

Advanced acral melanoma

Medicaid acceptance among pediatric dermatologists

Kaposi sarcoma presenting as a cutaneous horn

Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? Michael A. Marchetti, MD, Edmund K. Bartlett,

Identification of novel targetable mutations in metastatic anorectal melanoma by next- generation sequencing Emily D. Cai, BA, Jinah Kim, MD, PhD JAAD.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Tofacitinib therapy for children with severe alopecia areata

Violaceous plaque on the forehead clinically resembling angiosarcoma: Cutaneous metastasis in a patient with prostatic adenocarcinoma John S. Boswell,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Marked and restricted cutaneous pigmentation induced by selective intra-arterial cisplatin infusion Teruki Yanagi, MD, Masashi Akiyama, MD, PhD, Satoru.

Eccrine poroma in an unusual site: A clinical and dermoscopic simulator of amelanotic melanoma Davide Altamura, MD, Domenico Piccolo, MD, Gian Piero.

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Acanthosis nigricans in a patient with sarcoma of unknown origin

Chieko Sadahira, MD, Kozo Yoneda, MD, PhD, Yasuo Kubota, MD, PhD

Application of a Filtration- and Isolation-by-Size Technique for the Detection of Circulating Tumor Cells in Cutaneous Melanoma Vincenzo De Giorgi, Pamela.

Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC) Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Thrombophilic status may predict prognosis in patients with metastatic BRAFV600- mutated melanoma who are receiving BRAF inhibitors Anna Falanga, MD, Marina Marchetti, PhD, Daniela Massi, MD, Barbara Merelli, MD, Cristina Verzeroli, PhD, Laura Russo, PhD, Eliana Rulli, MSc, Carlo Tondini, MD, Lorenzo Legramandi, BSc, Romina Nassini, PhD, Cristian Scatena, MD, Francesco De Logu, PhD, Laura Cattaneo, MD, Mario Mandalà, MD Journal of the American Academy of Dermatology Volume 74, Issue 6, Pages 1254-1256.e4 (June 2016) DOI: 10.1016/j.jaad.2015.11.006 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Kaplan–Meier curves for D-dimer levels. A, Progression-free survival curves. Group 1: D-dimer at baseline <161.5 and D-dimer <349 at subsequent visit. Group 2: D-dimer at baseline <161.5 and D-dimer ≥349 at subsequent visit. Group 3: D-dimer at baseline ≥161.5. B, Overall survival curves. Group 1: D-dimer at baseline <433.5 and D-dimer <149.5 at subsequent visit. Group 2: D-dimer at baseline <433.5 and D-dimer ≥149.5 at subsequent visit. Group 3: D-dimer at baseline ≥433.5. Journal of the American Academy of Dermatology 2016 74, 1254-1256.e4DOI: (10.1016/j.jaad.2015.11.006) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1S Protease-activated receptor (PAR)-1 and tissue factor (TF) immunohistochemical expression in melanoma tissues. A, Weak PAR-1 staining in melanoma cells. B, Q14 PAR-1 is strongly and diffusely expressed in melanoma cells. Note that endothelial cells decorating blood vessels express PAR-1 protein. C, Example of PAR-1 staining in melanoma Q15 tissues. Both cytoplasmic and membranous positivity is observed in tumor cells; scattered stromal fibroblasts and macrophages are also positive. D,Weak and focal TF immunostaining in scattered melanoma cells. E, Aggregates of melanoma cells with strong TF cytoplasmic positivity. TF is also expressed in intratumoral flattened vascular endothelial cells. F, Strong TF cytoplasmic immunostain (red) in highly pigmented melanoma cells, partly colocalizes with melanin pigment (brown). Note the presence of abundant extracellular granular melanin depositions within the tumor. Scale bar = 50 μm. (A to F, Original magnification: ×40.) Journal of the American Academy of Dermatology 2016 74, 1254-1256.e4DOI: (10.1016/j.jaad.2015.11.006) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions